Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses

This feature was developed from a chapter presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Case Series: Click here to access the case series.

Part II: Case Series: Acute Agitation, Delirium, and Sleep Management

This feature was developed from a chapter presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Case Series: Click here to access the case series.

Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses

Authors: Ryan Feldman, Pharm.D., BCPS, DABAT; and James Leonard, Pharm.D., DABAT
Reviewed by: Julianne Yeary, Pharm.D., BCCCP; and Monica Owen, Pharm.D., BCPS, BCCCP

Part II: Case Series: Acute Agitation, Delirium, and Sleep Management

Author: Zachary R. Smith, Pharm.D., FCCP, BCPS, BCCCP
Reviewed by: Craig B. Whitman, Pharm.D., FCCM, BCCCP; and Megan Kaiser, Pharm.D., BCPS, BCGP

Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Classify prescription drug overdose by patient presentations.
2. Evaluate the causative agents of a drug overdose based on history and clinical findings of presentation.
3. Develop a treatment paradigm that may be applied in all prescription drug overdoses.
4. Assess the relevance of each therapeutic target in drug overdose in a specific drug overdose scenario.
5. Devise a plan for treatment of anticholinergic, sodium channel blocker, tricyclic antidepressant, bupropion, digoxin, sulfonylurea, alpha-2 agonist, iron, valproic acid, clonidine, and salicylate overdose.
6. Justify the use of specific antidotes in overdose.

Part II: Case Series: Acute Agitation, Delirium, and Sleep Management

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Apply bedside clinical assessment tools to detect pain, agitation, and delirium in the critically ill patient.
2. Design an evidence-based pharmacotherapy regimen for agitation in the critically ill patient.
3. Evaluate pharmacologic approaches for prevention and management of ICU delirium.
4. Assess therapeutic approaches to improve sleep quality in critically ill patients.
5. Develop a population-based approach for agitation, delirium, and sleep disturbance management in the ICU.

Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses

Consultancies: Ryan Feldman (Department of Health Services); James Leonard (Westat)
Honoraria: Ryan Feldman (ASHP/ACCP) Nothing to disclose: Julianne Yeary, Monica Owen

Part II: Case Series: Acute Agitation, Delirium, and Sleep Management

Grants: Zachary R. Smith (Shields Health Solution)
Nothing to disclose: Craig B. Whitman, Megan Kaiser

Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses

Universal Activity Number: 0217-0000-24-013-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Case Series: Acute Agitation, Delirium, and Sleep Management

Universal Activity Number: 0217-0000-24-014-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Interactive case: Click here to access the interactive case.

Part II: Interactive Case: Rapid Sequence Intubation

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Author: Emily J. Owen, Pharm.D., MS, BCPS, BCCCP
Reviewed by: Jenna Goetz, Pharm.D., BCPS, BCCCP; and Rizah Anwar Assadi, Pharm.D., BCPS

Part II: Interactive Case: Rapid Sequence Intubation

Author: Madeline Jane Foertsch, Pharm.D., BCCCP
Reviewed by: Matthew J. Campbell, Pharm.D., BCPS, BCCCP; and Andrea Boland, Pharm.D., BCPS

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Classify antithrombotic agents according to labeled indication, mechanism of action, and pharmacokinetic properties.
2. Assess life-threatening bleeding events caused by antithrombotic agents for treatment.
3. Evaluate the risk-benefit of treatments for life-threatening bleeding in the setting of an antithrombotic agent.
4. Develop an appropriate drug-dose regimen for a patient with life-threatening bleeding associated with an antithrombotic agent.

Part II: Interactive Case: Rapid Sequence Intubation

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Assess the pharmacologic properties and indication or pretreatment agents used in rapid sequence intubation (RSI).
2. Evaluate the pharmacologic properties of induction agents used in RSI.
3. Distinguish the pharmacologic properties of neuromuscular blocking agents used in RSI.
4. Design appropriate patient-specific RSI regimens, and incorporate patient disease state interactions into them.

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Emily Owen: Consultancies (Mallinckrodt); Honoraria (Mallinckrodt)
Nothing to disclose: Rizah Anwar Assadi, Jenna Goetz

Part II: Interactive Case: Rapid Sequence Intubation

Matthew J. Campbell: Grants (Spero Therapeutics)
Andrea Boland: Consultancies (Arkansas Association of Hospital Pharmacists)
Nothing to disclose: Madeline Jane Foertsch

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Universal Activity Number: 0217-0000-23-223-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Rapid Sequence Intubation

Universal Activity Number: 0217-0000-23-224-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

This feature was developed from a live program presented in October 2022 at the ACCP Global Conference in San Francisco.

• Recorded Webcast: Click here to access the Recorded webcast.
• PDF Transcript: Click here to access the PDF Transcript.

Part II: Critical Evaluation of Kidney Function

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive case: Click here to access the interactive case.

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Presenters: Craig J. Beavers, Pharm.D., FCCP, FACC, FAHA, BCCP, BCPS-AQ Cardiology, CACP; Kelly M. Rudd, Pharm.D., FCCP, BCPS; and Stephanie Dwyer Kaluzna, Pharm.D., BCCP
Reviewed by: Stormi E. Gale, Pharm.D., BCPS, BCCP; Candace Bryant, Pharm.D., BCPS; and A. Joshua Roberts, Pharm.D., BCCP, BCPS, AACC

Part II: Interactive Case: Critical Evaluation of Kidney Function

Authors: Ayesha M. Khan, Pharm.D., BCPS; and Gary D. Peksa, Pharm.D., MBA, BCPS
Reviewed by: Wendy St. Peter, Pharm.D.; and Bryn Lindley, Pharm.D., BCPS

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with one or more common cardiac conditions or disorders.

Learning Objectives

1. Distinguish the incidence, pathophysiology, risk factors, and clinical presentation associated with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
2. Examine the clinical efficacy and safety data associated with agents recommended for the treatment of HFpEF.
3. Develop a pharmacologic treatment plan for HFrEF and HFpEF that optimizes the use of guideline-directed medical therapy.
4. Distinguish the thrombotic pathophysiology of antiphospholipid syndrome (APS).
5. Evaluate available evidence pertaining to the use of anticoagulants in patients with APS.
6. Develop an appropriate guideline-driven pharmacotherapeutic treatment plan for a patient with APS.
7. Design an antithrombotic treatment plan for a patient undergoing coronary stenting.
8. Analyze recent literature surrounding modified regimens of dual antiplatelet therapy in patients with coronary artery disease and acute coronary syndromes.
9. Distinguish between the various antithrombotic treatment regimens indicated for patients undergoing transcatheter aortic valve implantation.

Part II: Interactive Case: Critical Evaluation of Kidney Function

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Assess different methods in evaluating kidney function.
2. Develop patient care plans that equitably and safely address patients with kidney dysfunction.
3. Evaluate the influence of patient-specific factors on drug disposition.
4. Distinguish factors that must be considered when designing a drug dosing regimen for a patient with kidney impairment.

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Nothing to disclose: Craig J. Beavers, Candace Bryant, Stormi E. Gale, Stephanie Dwyer Kaluzna, A. Joshua Roberts, Kelly M. Rudd

Part II: Interactive Case: Critical Evaluation of Kidney Function

Consultancies: Wendy St. Peter (Glaxosmithkline)
Nothing to disclose: Ayesha M. Khan, Bryn Lindley, Gary D. Peksa

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Universal Activity Number: 0217-0000-23-152-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Critical Evaluation of Kidney Function

Universal Activity Number: 0217-0000-23-153-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Menopause

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive Case: Click here to access the interactive case.

Part II: Interactive Case: Drug-Induced Endocrine Disorders

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Menopause

Authors: Nicole E. Cieri-Hutcherson, Pharm.D., BCPS, NCMP; and Veronica Vernon, Pharm.D., BCPS, BCACP, NCMP
Reviewed by: Sarah M. Westberg, Pharm.D., FCCP, BCPS; and Abigail M. Yancey, Pharm.D., FCCP, BCPS

Part II: Interactive Case: Drug-Induced Endocrine Disorders

Author: Amy C. Donihi, Pharm.D., FCCP, BCPS, BC-ADM
Reviewed by: Krystal KC Riccio, Pharm.D., BCACP, CDCES; and Eman Elsayed Younis, Pharm.D., BCPS AQ-Cardiology

Part I: Interactive Case: Menopause

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Evaluate a patient for the appropriate use and initiation of menopausal hormone therapy (MHT).
2. Apply updates from guidelines and recent analyses of the Women’s Health Initiative data to the treatment of menopause and osteoporosis.
3. Develop appropriate nonpharmacologic and pharmacologic interventions for vasomotor symptoms of menopause and genitourinary syndrome of menopause.
4. Design a monitoring plan to assess the safety and effectiveness of pharmacotherapy for a patient using MHT.
5. Justify appropriate screening, diagnosis, and treatment of postmenopausal osteoporosis.

Part II: Interactive Case: Drug-Induced Endocrine Disorders

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Develop a screening and treatment plan for a patient with or at risk of drug-induced endocrine abnormalities with checkpoint inhibitors.
2. Design a screening and treatment plan for a patient with or at risk of drug-induced thyroid disorders.
3. Devise a screening and treatment plan for a patient with or at risk of drug-induced osteoporosis.
4. Develop a screening and treatment plan for a patient with or at risk of drug-induced hyperglycemia.
5. Evaluate patients for possible drug interference with diagnostic endocrine laboratory tests.

Part I: Interactive Case: Menopause

Consultancies: Sarah M. Westberg (Minnesota Pharmacists Association)
Nothing to disclose: Nicole E. Cieri-Hutcherson, Veronica Vernon, Abigail M. Yancey

Part II: Interactive Case: Drug-Induced Endocrine Disorders

Nothing to disclose: Amy C. Donihi, Krystal KC Riccio, Eman Elsayed Younis

Part I: Interactive Case: Menopause

Universal Activity Number: 0217-0000-23-073-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Drug-Induced Endocrine Disorders

Universal Activity Number: 0217-0000-23-074-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Precision Medicine in Psychiatry

This feature was developed from an interactive case presented in PSAP 2022 Book 3 (Behavioral Health).

• Interactive Case: Click here to access the interactive case.

Part II: Interactive Case: Clinical Pearls of Clozapine

This feature was developed from an interactive case presented in PSAP 2022 Book 3 (Behavioral Health).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Precision Medicine in Psychiatry

Authors: Jonathan F. Lister, Pharm.D., BCPP; and Kara R. Wong, Pharm.D., BCPP
Reviewed by: Jacob T. Brown, Pharm.D., MS; Rizah Anwar Assadi, Pharm.D., BCPS; and Michelle Ganoff, Pharm.D., BCPS

Part II: Interactive Case: Clinical Pearls of Clozapine

Author: Jonathan G. Leung, Pharm.D., BCPS, BCPP
Reviewed by: Erica Davis, Pharm.D., BCPS, BCPP; Alisa Brown Chamblee, Pharm.D., BCPS; and Asmaa Kamal Mohammed, Pharm.D., BCPS

Part I: Interactive Case: Precision Medicine in Psychiatry

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Evaluate the evidence and guideline recommendations for pharmacogenomic (PGx) testing and therapeutic drug monitoring (TDM) in psychiatry.
2. Distinguish when a patient may benefit from PGx testing and TDM in psychiatry.
3. Assess psychiatric PGx and TDM results in a patient with mental illness.
4. Develop a treatment plan, including patient counseling, using PGx and/or TDM results for a patient with mental illness

Part II: Interactive Case: Clinical Pearls of Clozapine

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Develop a treatment plan involving clozapine using current evidence and clinical guidelines.
2. Assess patients for clinically relevant drug interactions with clozapine.
3. Justify the role of monitoring clozapine and norclozapine serum concentrations in clinical practice.
4. Account for potential clozapine-related adverse events during and after an acute hospital admission

Part I: Interactive Case: Precision Medicine in Psychiatry

Kara R. Wong: Consultancies (CPNP Recertification Editorial Board); Honoraria (College of Psychiatric and Neurologic Pharmacists)
Nothing to disclose: Rizah Anwar Assadi, Jacob T. Brown, Michelle Ganoff, Jonathan F. Lister

Part II: Interactive Case: Clinical Pearls of Clozapine

Jonathan G. Leung: Consultancies (Wolters-Kluwer)
Nothing to disclose: Erica Davis, Alisa Brown Chamblee, Asmaa Kamal Mohammed

Part I: Interactive Case: Precision Medicine in Psychiatry

Universal Activity Number: 0217-0000-23-009-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Clinical Pearls of Clozapine

Universal Activity Number: 0217-0000-23-010-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Management of Urgent Drug Shortages

This feature was developed from an interactive case presented in PSAP 2022 Book 2 (Current Issues in Pharmacotherapy).

• Interactive Case: Click here to access the interactive case.

Part II: Interactive Case: Toxicology and Poison Control

This feature was developed from an interactive case presented in PSAP 2022 Book 2 (Current Issues in Pharmacotherapy).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Management of Urgent Drug Shortages

Author: Milena Murray, Pharm.D., FCCP, BCIDP, AAHIVP
Reviewed by: Joshua P. Vanderloo, Pharm.D., BCPS; and Marianne Billeter, Pharm.D., BCPS

Part II: Interactive Case: Toxicology and Poison Control

Author: Matthew T. Stanton, Pharm.D., BCPS, DABAT
Reviewed by: Renee Petzel Gimbar, Pharm.D., FAACT; Megan E. Phillips, Pharm.D., BCPS, C-ELBW; and Samantha F. Geishauser, Pharm.D., BCPS

Part I: Interactive Case: Management of Urgent Drug Shortages

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Distinguish drug shortage causes on the basis of supply and demand.
2. Analyze patient care outcomes and risks because of drug shortages.
3. Design an appropriate management program for drug shortages.
4. Design an appropriate management program for drug shortages.
5. Resolve ethical issues related to drug shortages.

Part II: Interactive Case: Toxicology and Poison Control

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Justify the role of poison control centers in current and future toxicology practice.
2. Distinguish among the current treatments of acetaminophen toxicity.
3. Assess the role and place in therapy of physostigmine and rivastigmine for anticholinergic toxicity.
4. Evaluate a patient with methanol or ethylene glycol toxicity.
5. Design a therapeutic regimen for a patient with β-blocker or calcium channel blocker poisoning.

Part I: Interactive Case: Management of Urgent Drug Shortages

Milena M. Murray: Consultancies (VIIV; Theratechnologies); Honoraria (Merck)
Joshua Vanderloo: Consultancies (Quartz Insurance)
Nothing to disclose: Marianne Billeter

Part II: Interactive Case: Toxicology and Poison Control

Renee Petzel Gimbar: Consultancies (Fresenius Kabi; ASHP); Grants (NIH; Xeris Pharmaceuticals)
Nothing to disclose: Samantha F. Geishauser, Megan E. Phillips, Matthew T. Stanton

Part I: Interactive Case: Management of Urgent Drug Shortages

Universal Activity Number: 0217-0000-22-247-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Toxicology and Poison Control

Universal Activity Number: 0217-0000-22-248-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Hyperlipidemia Management for Special Populations

This feature was developed from an interactive case presented in PSAP 2022 Book 1 (Cardiology).

• Interactive Case: Click here to access the interactive case.

Part II: Interactive Case: Cardiovascular Diseases in Pregnancy

This feature was developed from an interactive case presented in PSAP 2022 Book 1 (Cardiology).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Hyperlipidemia Management for Special Populations

Authors: Glenn Herrington, Pharm.D., AACC, BCCP, BCPS, CDCES; and Daniel M. Riche, Pharm.D., FCCP, CLS, ASH-CHC
Reviewed by: Elisabeth M. Wang, Pharm.D., BCCP; Jessica Bente, Pharm.D., BCPS, BCGP; and Eman Elsayed Younis, Pharm.D., BCPS-AQ Cardiology

Part II: Interactive Case: Cardiovascular Diseases in Pregnancy

Author: Lindsey Federle, Pharm.D., BCCP, BCPS
Reviewed by: Jessie Dunne, Pharm.D., BCPS, BCCP; and Leslie Wooten, Pharm.D., BCPS

Part I: Interactive Case: Hyperlipidemia Management for Special Populations

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering diverse cardiovascular patient populations.

Learning Objectives

1. Evaluate cardiovascular risk and complications to apply pharmacologic management strategies for hyperlipidemia in older adult patients.
2. Apply pharmacologic management strategies for hyperlipidemia in patients of various racial/ethnic backgrounds.
3. Apply pharmacologic management strategies for hyperlipidemia in patients with HIV infection.
4. Apply pharmacologic management strategies for familial hyperlipidemia.

Part II: Interactive Case: Cardiovascular Diseases in Pregnancy

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering diverse cardiovascular patient populations.

Learning Objectives

1. Evaluate patient risk factors for cardiovascular complications during pregnancy and stratify according to the modified WHO pregnancy risk classes.
2. Distinguish the physiologic and pharmacokinetic changes that occur in pregnancy.
3. Assess hypertensive disorders of pregnancy and devise treatment plans throughout pregnancy.
4. Develop an appropriate medical regimen for peripartum cardiomyopathy.
5. Design safe and effective anticoagulant regimens during pregnancy.
6. Develop pharmacotherapy to manage acute arrhythmia in the pregnant patient.

Part I: Interactive Case: Hyperlipidemia Management for Special Populations

Daniel M. Riche: Consultancies (Novo Nordisk; Merck; AstraZeneca); Royalties (McGraw-Hill)
Jessica Bente: Grants (New Jersey Society of Health-System Pharmacists)
Nothing to disclose: Glenn Herrington, Elisabeth M. Wang, Eman Elsayed Younis

Part II: Interactive Case: Cardiovascular Diseases in Pregnancy

Jessie Dunne: Consultancies (Pulmonary Hypertension Association)
Nothing to disclose: Lindsey Federle, Leslie Wooten

Part I: Interactive Case: Hyperlipidemia Management for Special Populations

Universal Activity Number: 0217-0000-22-086-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Cardiovascular Diseases in Pregnancy

Universal Activity Number: 0217-0000-22-087-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Psoriasis

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

• Interactive Case: Click here to access the interactive case.

Part II: Interactive Case: Combination Therapies in BPH

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Psoriasis

Author: Timothy D. Gladwell, Pharm.D., BCPS, BCACP
Reviewed by: Rebecca M. Law, Pharm.D.; Ann Nadrash, Pharm.D., BCPS; and Kimberly N. Blanton, Pharm.D., BCPS

Part II: Interactive Case: Combination Therapies in BPH

Authors: Mary Barna Bridgeman, Pharm.D., FCCP, FNAP, BCPS, BCGP; and Luigi Brunetti, Pharm.D., MPH, BCPS, BCGP
Reviewed by: Kathy Eroschenko, Pharm.D.; Tara B. Vlasimsky, Pharm.D., BCPS, BCACP; and Daniel Majerczyk, Pharm.D., BCPS, BC-ADM, CACP

Part I: Interactive Case: Psoriasis

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

1. Apply data from contemporary studies of epidemiology and pathophysiology to the assessment and treatment of patients with psoriasis.
2. Evaluate the severity of a patient’s psoriasis in order to justify a general treatment approach.
3. Develop an evidence-based treatment regimen to manage the clinical manifestations of a patient’s psoriasis.
4. Develop a plan for screening and managing psoriasis-related comorbidities and adverse effects of therapy according to current guidelines.
5. Design a treatment plan to manage special populations of patients with psoriasis.

Part II: Interactive Case: Combination Therapies in BPH

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

1. Evaluate combination pharmacologic agents for the treatment of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), including adverse effects and monitoring.
2. Design an appropriate treatment approach for a patient with BPH/LUTS, including the role of combination therapy.

Part I: Interactive Case: Psoriasis

Rebecca Law: Royalties (McGraw-Hill, Springer Nature); Consultancies (Memorial University of Newfoundland); Honoraria (Memorial University of Newfoundland Faculty of Medicine
Kimberly N. Blanton; Timothy D. Gladwell; Ann Nadrash: Nothing to disclose

Part II: Interactive Case: Combination Therapies in BPH

Mary Barna Bridgeman: Grants (Merck and Co.); Honoraria (AstraZeneca)
Luigi Brunetti: Consultancies (Tabula Rasa Healthcare, Horizon Blue Cross Blue Shield of New Jersey); Grants (Merck and Co., CSL Behring, Innovative Research)
Kathy Eroschenko: Grants (Idaho Office of Drug Policy)
Tara B. Vlasimsky: Stock Ownership (Imidex)
Daniel Majerczyk: Nothing to disclose

Part I: Interactive Case: Psoriasis

Universal Activity Number: 0217-0000-22-072-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Combination Therapies in BPH

Universal Activity Number: 0217-0000-22-073-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Rational Deprescribing of Benzodiazepine Receptor Agonists for Insomnia

This feature was developed from an interactive case presented in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive Case: Click here to access the interactive case.

Part II: Statistics in Practice: Study Design and Application of Inferential Statistics – Interventional Research

This feature was developed from an interactive case appearing in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Rational Deprescribing of Benzodiazepine Receptor Agonists for Insomnia

Author: Barbara Farrell, Pharm.D., ACPR, FCSHP
Reviewed by: Kristina M. Ward, Pharm.D., BCPS, BCPP; and Amanda McFee Winans, Pharm.D., BCPS, CACP

Part II: Statistics in Practice: Study Design and Application of Inferential Statistics – Interventional Research

Author: David R. Foster, Pharm.D., FCCP; and Kevin M. Sowinski, Pharm.D., FCCP
Reviewed by: Curtis E. Haas, Pharm.D., FCCP; Micheline Goldwire, Pharm.D., MS, BS, BCPS; and Tanvi Patil, Pharm.D., BCPS

Part I: Interactive Case: Rational Deprescribing of Benzodiazepine Receptor Agonists for Insomnia

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with psychiatric and neurologic diseases.

Learning Objectives

1. Evaluate patients with insomnia for appropriateness of benzodiazepine receptor agonist (BZRA) deprescribing.
2. Apply patient engagement and shared decision-making approaches to facilitate BZRA deprescribing.
3. Design, implement, and monitor BZRA deprescribing plans for patients with insomnia.
4. Develop nonpharmacologic support plans for insomnia during and after BZRA deprescribing.

Part II: Statistics in Practice: Study Design and Application of Inferential Statistics – Interventional Research

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Evaluate appropriate clinical trial study design elements, including considerations of randomization and blinding.
2. Distinguish clinical trial design features including subgroup analyses, composite endpoints, early cessation, surrogate endpoints, non-randomized designs, and internal/external validity.
3. Assess event rates or risks observed in clinical trials.
4. Compute and evaluate absolute risk reduction, relative risk reduction and number needed to treat.
5. Identify decision errors (Type I, Type II error) encountered in clinical trials.
6. Justify the use of components necessary for sample size estimation in clinical trials.

Part I: Interactive Case: Rational Deprescribing of Benzodiazepine Receptor Agonists for Insomnia

Barbara Farrell: Grants (CABHI Spark Program; Government of Ontario through the Bruyere Centre for Learning, Research and Innovation in Long-term Care; Canadian Institutes of Health Research; Canadian Foundation for Healthcare Improvement and Canadian Frailty Network; The Ottawa Hospital Academic Medical Organization); Honoraria (Pacific Psychopharmacology Conference, Canada; Ontario Long-Term Care Clinicians, Canada; The University of Bath; ASHP; National University Hospital, Singapore; Peterborough Regional Health Centre; Copenhagen University Hospital Bispebjerg; Canadian Foundation for Healthcare Improvement; Canadian Society of Hospital Pharmacists)
Kristina M. Ward: Honoraria (College of Psychiatric and Neurologic Pharmacists; ASHP)
Amanda McFee Winans: Nothing to disclose

Part II: Statistics in Practice: Study Design and Application of Inferential Statistics – Interventional Research

David R. Foster, Kevin M. Sowinski, and Tanvi Patil: Nothing to disclose
Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Micheline Goldwire: Honoraria (Alliance for Pharmacy Compounding)

Part I: Interactive Case: Rational Deprescribing of Benzodiazepine Receptor Agonists for Insomnia

Universal Activity Number: 0217-0000-22-017-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Statistics in Practice: Study Design and Application of Inferential Statistics – Interventional Research

Universal Activity Number: 0217-0000-22-018-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Adverse Effects Associated with Antipsychotic Therapy

This feature was developed from an interactive case presented in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive Case: Click here to access the interactive case.

Part II: Statistics in Practice: Survival Analysis and Common Applications

This feature was developed from an interactive case appearing in PSAP 2021 Book 1 (Infectious Diseases).

• Interactive case: Click here to access the interactive case.

Part I: Interactive Case: Adverse Effects Associated with Antipsychotic Therapy

Author: Kristen N. Gardner, Pharm.D., BCPP
Reviewed by: Roger W. Sommi, Pharm.D., FCCP, BCPP; Jennifer Bean, Pharm.D., BCPS, BCPP; and Lauren Schmidt, Pharm.D., BCPS

Part II: Statistics in Practice: Survival Analysis and Common Applications

Author: Daniel R. Touchette, Pharm.D., M.A., FCCP; and Ryan Rodriguez, Pharm.D., BCPS
Reviewed by: Kevin Sowinski, Pharm.D., FCCP; Haley Ilcewicz, Pharm.D., BCPS; and Kerry Anne Rambaran, Pharm.D., BCPS

Part I: Interactive Case: Adverse Effects Associated with Antipsychotic Therapy

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with psychiatric and neurologic diseases.

Learning Objectives

1. Evaluate differential risk of antipsychotic adverse effects and monitor accordingly.
2. Design a pharmacotherapeutic plan for a patient with antipsychotic-related metabolic syndrome.
3. Assess patients for common antipsychotic-related movement disorders.
4. Distinguish among pharmacotherapy options for tardive dyskinesia management.

Part II: Statistics in Practice: Survival Analysis and Common Applications

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Assess data used in survival analysis, including censored observations.
2. Interpret results from Kaplan-Meier curves, Cox proportional hazards models, and log-rank tests.
3. Determine the most appropriate survival analysis to perform, including when the assumption of proportional hazards is not met.

Part I: Interactive Case: Adverse Effects Associated with Antipsychotic Therapy

Kristen N. Gardner: Consultancies (Biostrategies)
Roger W. Sommi: Grants (Alkermes; Neurocrine; Boeringer Ingelheim); Honoraria (Alkermes; Intracellular Therapies; Sunovion)
Jennifer Bean, Lauren J. Schmidt: Nothing to disclose

Part II: Statistics in Practice: Survival Analysis and Common Applications

Touchette (Consultancies: Institute for Clinical and Economic Review, Monument Analytics); Grants Institute for Clinical and Economic Review)
Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Ryan Rodriguez: Honoraria (ACCP)
Haley Ilcewicz, Kerry Anne Rambaran: Nothing to disclose

Part I: Interactive Case: Adverse Effects Associated with Antipsychotic Therapy

Universal Activity Number: 0217-0000-21-267-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Statistics in Practice: Survival Analysis and Common Applications

Universal Activity Number: 0217-0000-21-268-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: Interactive Case: Strategies for Antimicrobial Optimization

This feature was developed from an interactive case appearing in PSAP 2021 Book 1 (Infectious Diseases).

• Interactive Case: Click here to begin this activity.

Part II: Statistics in Practice: Regression and Correlation, Part 2

This feature was developed from an interactive case appearing in PSAP 2020 Book 3 (Hematology and Oncology).

• Interactive case: Click here to begin this activity.

Part I: Interactive Case: Strategies for Antimicrobial Optimization

Author: Heather Gibson, Pharm.D., BCIDP, BCPS is and Antimicrobial Stewardship Pharmacist for the Departments of Infection Control and Pharmacy, FirstHealth of the Carolinas Moore Regional Hospital, Pinehurst, North Carolina.
Reviewed by: Dana R. Bowers, Pharm.D., BCPS-AQ ID, BCIDP; and Samantha Yeates, Pharm.D., BCPS

Part II: Statistics in Practice: Regression and Correlation, Part 2

Author: Curtis E. Haas, Pharm.D., FCCP, is Director of Pharmacy at the University of Rochester Medical Center in Rochester, New York.
Reviewed by: Daniel R. Touchette, Pharm.D., MA, FCCP; and Lan N. Bui, Pharm.D., MPH, BCPS

Part I: Interactive Case: Strategies for Antimicrobial Optimization

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists encountering patients with infectious diseases.

Learning Objectives

1. Assess the use of antibiotic optimization strategies as antimicrobial stewardship initiatives.
2. Analyze the data supporting the use of each optimization strategy to determine its clinical effectiveness and place in practice.
3. Evaluate patient profiles to determine which optimization strategies are appropriate to use to improve patient outcomes.

Part II: Statistics in Practice: Regression and Correlation, Part 2

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Distinguish regression from correlation models and how each is applied to the analysis and understanding of clinical data.
2. Evaluate the results of common regression and correlation models, and how these results can be used in the interpretation and application of clinical data.
3. Apply the results of a multiple regression model in the analysis of clinical trial data, including how independent variables are best selected for a multiple regression model.
4. Evaluate results from a non-parametric Spearman Rank Order Correlation model.
5. Justify the use of common generalized linear models in regression analysis of different response variable types.

Part I: Interactive Case: Strategies for Antimicrobial Optimization

Heather Gibson, Dana Bowers, Samantha Yeates: Nothing to disclose

Part II: Statistics in Practice: Regression and Correlation, Part 2

Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Daniel R. Touchette (Consultancies: Institute for Clinical and Economic Review, Monument Analytics); (Grants Institute for Clinical and Economic Review)
Lan Bui: Nothing to disclose

Part I: Interactive Case: Strategies for Antimicrobial Optimization

Universal Activity Number: 0217-0000-21-233-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Statistics in Practice: Regression and Correlation, Part 2

Universal Activity Number: 0217-0000-21-234-H04-P
1.5 CPE contact hours
Application-Based Activity

Part I: PSAP Live: Optimizing Care in Type 2 Diabetes: Evidence-Based Treatment Design and Therapy Intensification

This feature was developed from the PSAP Live program presented virtually on Friday, October 20, 2020 as part of the ACCP Annual Meeting.

• Recorded webcast: Click here to begin this activity.

Part II: Statistics in Practice: Regression and Correlation, Part I

This feature was developed from a Statistics in Practice feature appearing in PSAP 2020 Book 2 (Pulmonary and Gastroenterology).

• Interactive case: Click here to begin this activity.

Part I: PSAP Live: Optimizing Care in Type 2 Diabetes: Evidence-Based Treatment Design and Therapy Intensification

Moderator: Mary Wun-Len Lee, Pharm.D., BCPS, is Vice President and Special Assistant to the President, Midwestern University; Professor of Pharmacy Practice, Chicago College of Pharmacy, Downers Grove, Illinois
Presenters: Nicholas Messinger, Pharm.D., BCPS, BCACP, CDCES, BC-ADM, is an Associate Professor – Clinical, Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, Ohio; Jennifer Trujillo, Pharm.D., FCCP, BCPS, CDCES, BC-ADM, is an Associate Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado; and Diana Isaacs, Pharm.D., BCPS, BCACP, BC-ADM, CDCES, FADCES, is a Clinical Pharmacy Specialist, Endocrinology & Metabolism Institute, Diabetes Center, Cleveland Clinic, Cleveland, Ohio
Reviewed by: Alexander R. Hoffman, Pharm.D., BCPS, CDCES; Brian K. Irons, Pharm.D., FCCP, BCACP; and Christine A. Schumacher, Pharm.D, FCCP, BCPS, BCACP, BCPP, BC-ADM, CDCES

Part II: Statistics in Practice: Regression and Correlation, Part I

Author: Curtis E. Haas, Pharm.D., FCCP, is the Director of Pharmacy, Department of Pharmacy, University of Rochester Medical Center, Rochester, New York.
Reviewed by: Daniel R. Touchette, Pharm.D., MA, FCCP; and Lan N. Bui, Pharm.D., MPH, BCPS

Part I: PSAP Live: Optimizing Care in Type 2 Diabetes: Evidence-Based Treatment Design and Therapy Intensification

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists encountering patients with disorders requiring pharmacotherapy for type 2 diabetes.

Learning Objectives

1. Evaluate glucose-lowering agents on the basis of their cardiovascular outcomes, effects on weight, cost, and risk of hypoglycemia.
2. Apply diabetes treatment algorithms when intensifying drug therapy for patients with type 2 diabetes.
3. Develop a plan to safely initiate and intensify insulin therapy on the basis of guideline recommendations and patient-specific factors.
4. On the basis of hypoglycemia, hyperglycemia, or other treatment considerations, justify the use of pattern management skills in adjusting insulin treatment plans.
5. Evaluate the use of continuous glucose monitoring devices and connected pens in the management of diabetes.
6. Using connected data, design pharmacotherapy for a patient with diabetes.

Part II: Statistics in Practice: Regression and Correlation, Part I

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Distinguish regression from correlation models and how each is applied to the analysis and understanding of clinical data.
2. Evaluate the results of common regression and correlation models, and how these results can be used in the interpretation and application of clinical data.
3. Apply the results of a multiple regression model in the analysis of clinical trial data, including how independent variables are best selected for a multiple regression model.
4. Evaluate results from a non-parametric Spearman Rank Order Correlation model.
5. Justify the use of common generalized linear models in regression analysis of different response variable types.

Part I: PSAP Live: Optimizing Care in Type 2 Diabetes: Evidence-Based Treatment Design and Therapy Intensification

Alexander R. Hoffman: Consultancies (Ohio Society of Health-Systems Pharmacy; Ohio College of Clinical Pharmacy); Grants (Northeast Ohio Medical University); Honoraria (NEOVations)
Diana Isaacs: Consultancies (Abbott Diabetes, Dexcom, Novo Nordisk, Companion Medical, Lilly, LifeScan)
Mary Wun-Len Lee: Consultancies (ACCP, Higher Learning Commission); Royalties (ASHP)
Christine A. Schumacher: Consultancies (Sanofi)
Jennifer Trujillo: Consultancies (BD, Novo Nordisk)
Nicholas Messinger, Brian K. Irons: Nothing to disclose

Part II: Statistics in Practice: Regression and Correlation, Part I

Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Daniel R. Touchette: (Consultancies: Institute for Clinical and Economic Review, Monument Analytics); (Grants Institute for Clinical and Economic Review)
Lan Bui: Nothing to disclose

Part I: PSAP Live: Optimizing Care in Type 2 Diabetes: Evidence-Based Treatment Design and Therapy Intensification

Universal Activity Number: 0217-0000-21-038-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Statistics in Practice: Regression and Correlation, Part I

Universal Activity Number: 0217-0000-21-039-H04-P
1.5 CPE contact hours
Application-Based Activity